Bayforest Capital LTD Bei Gene, Ltd. Transaction History
Bayforest Capital LTD
- $121 Billion
- Q1 2025
A detailed history of Bayforest Capital LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bayforest Capital LTD holds 1,129 shares of BGNE stock, worth $255,955. This represents 0.18% of its overall portfolio holdings.
Number of Shares
1,129Holding current value
$255,955% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
267Shares Held
42.3MCall Options Held
135KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...